Evaluating salivary RNAs in patients with ovarian masses
Official title: Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin - OVAmiARN Study
Run by Ziwig · NCT05514028 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if changes in saliva can help doctors diagnose and manage patients with ovarian masses, including cancer, before and after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 250 (estimated) |
| Sponsor | Ziwig Industry-sponsored |
| Locations | 12 sites (Caen, Calvados and 11 other locations) |
| Trial ID | NCT05514028 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with an ovarian adnexal mass diagnosed through clinical examination and imaging, who are scheduled for surgery.
✕Probably not a fit
Patients who are pregnant, have significant reading or writing difficulties in French, or have other diagnosed cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze the changes in salivary microRNA expression in patients diagnosed with ovarian adnexal masses, including ovarian cancer, borderline tumors, and benign cysts. Conducted across multiple obstetrics and gynecology departments in France, the study will track these changes from pre-operative to post-therapy visits without altering the standard care pathway. The goal is to enhance diagnostic speed and improve patient management for those requiring surgical intervention.
Why it matters
Potential benefit: If successful, this study could lead to faster diagnoses and better management strategies for patients with ovarian masses.
How similar studies have gone: While this approach is innovative in its focus on salivary RNAs for ovarian masses, similar studies using biomarkers for cancer diagnosis have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age, * A patient with an ovarian adnexal mass diagnosed by clinical examination and imaging and likely to be ovarian cancer, a borderline tumour or a benign cyst, * Patient with an indication for surgery * Patient has dated and signed the consent form, * Patient affiliated to the healthcare system, Exclusion Criteria: * Pregnant patient * Patient infected with human immunodeficiency virus (HIV), * Patient with significant difficulties in reading or writing the French language. * Patient with another diagnosed cancer * Patient with a history of cancer less than 5 years old
Where it's running
-
CHU de Caen
Caen, Calvados, France Recruiting -
CHU Angers
Angers, France Recruiting -
CH Bastia
Bastia, France Recruiting -
CHU Lyon Sud / Hospices Civils de Lyon
Lyon, France Recruiting -
Centre Antoine Lacassagne
Nice, France Recruiting -
CH Niort
Niort, France Recruiting
Show 6 more locations
-
CHU Tenon
Paris, France Recruiting -
CHU Rennes
Rennes, France Recruiting -
Clinique La sagesse
Rennes, France Recruiting -
CHU Rouen, Hôpital de Bois-Guillaume
Rouen, France Recruiting -
Clinique Pasteur
Toulouse, France Recruiting -
CHRU Bretonneau-Tours
Tours, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.